1. Home
  2. TTRX vs SVIA Comparison

TTRX vs SVIA Comparison

Compare TTRX & SVIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

SELL

Current Price

$11.11

Market Cap

298.8M

Sector

Health Care

ML Signal

SELL

SVIA

Silvia Inc. Common Stock

N/A

Current Price

$3.87

Market Cap

333.9M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TTRX
SVIA
Founded
2015
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
298.8M
333.9M
IPO Year
2025
2026

Fundamental Metrics

Financial Performance
Metric
TTRX
SVIA
Price
$11.11
$3.87
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $25.00
N/A
AVG Volume (30 Days)
145.0K
★ 1.5M
Earning Date
11-25-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$900.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$3.68
52 Week High
$16.45
$4.74

Technical Indicators

Market Signals
Indicator
TTRX
SVIA
Relative Strength Index (RSI) 42.42 47.35
Support Level $9.02 $3.71
Resistance Level $14.39 $4.74
Average True Range (ATR) 1.25 0.28
MACD -0.41 -0.02
Stochastic Oscillator 1.09 14.62

Price Performance

Historical Comparison
TTRX
SVIA

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: